Nowadays the diagnosis of breast cancer has ceased to be a life sentence. A tumor that is detected early can be removed, and subsequent chemotherapy can significantly reduce the chance of the tumor recurring.
But unfortunately, in many cases the malignant process can spread. In the case of breast cancer, the most dangerous form of this process is bone metastasis (most often hip, cranial, vertebral).
On the X-ray, the affected areas of the bones look either as voids or as spots with excessive formation of altered bone tissue. In this and in other cases, the affected bone becomes fragile and can easily break even from a small load. The factors responsible for these processes are well studied, which allows the cell culture to evaluate the possible antimetastatic effect of various anti-cancer drugs.
Tests of Neovastat AE-941 a natural multi-functional inhibitor of angiogenesis
An experimental model of breast cancer cells (MDA-MD-231) capable of forming bone metastasis was used to determine whether Neovastat is able to regulate the properties of cancer cells that form bone metastasis. It has been shown that Neovastat prevents bone degradation caused by cancer cells. Moreover, Neovastat demonstrated the ability to inhibit the activity of the enzyme metalloproteinase (MMP-9), by which cancer cells “melt” the intercellular gelatin-like substance and “leave” from the main tumor, creating the risk of distant metastasis.
The next stage of research was an experiment on mice, which introduced the culture of cancer cells MDA-MD-231. In the absence of any treatment, these cells are soon found in the bones, destroying the bone structure by 83%. However, when mice were given Neovastat daily, the medullary (abdominal) bones were destroyed by only 19%, which demonstrated the ability of Neovastat to prevent non-proliferation of bone metastasis in this experimental environment. In addition, a decrease in tumor volume was observed in mice receiving Neovastat.
These experimental results demonstrated that the drug Neovastat can help prevent bone metastasis, as well as inhibit the growth and spread of the destructive effects of cancer cells.
Clinical example: patient B., 57 years old, in 2002 she was diagnosed with breast cancer and metastasis in the ribs, the bones of the pelvis and skull. After surgery and poly-chemotherapy she took the drug Neovastat daily in 90 ml dosage. To the present day, the existing metastasis (tumor) did not increase in size, and no new metastatic lesions were detected. The condition is satisfactory.
Based on: Weber MH, Lee J, Orr FW. “The effects of Neovastat AE-941 on an experimental metastatic bone tumor model”.